[1]
|
Farrow, G.M., Harrison Jr., E.G., Utz, D.C. and Remine, W.H. (1968) Sarcomas and Sarcomatoid and Mixed Malignant Tumors of the Kidney in Adults—Part I. Cancer, 22, 545-550.
https://doi.org/10.1002/1097-0142(196809)22:3<545::AID-CNCR2820220308>3.0.CO;2-4
|
[2]
|
Shuch, B., Bratslavsky, G., Linehan, W.M. and Srinivasan, R. (2012) Sarcomatoid Renal Cell Carcinoma: A Comprehensive Re-view of the Biology and Current Treatment Strategies. The Oncologist, 17, 46-54.
https://doi.org/10.1634/theoncologist.2011-0227
|
[3]
|
Blum, K.A., Gupta, S., Tickoo, S.K., et al. (2020) Sarcoma-toid Renal Cell Carcinoma: Biology, Natural History and Management. Nature Reviews Urology, 17, 659-678. https://doi.org/10.1038/s41585-020-00382-9
|
[4]
|
Mian, B.M., Bhadkamkar, N., Slaton, J.W., et al. (2002) Prog-nostic Factors and Survival of Patients with Sarcomatoid Renal Cell Carcinoma. The Journal of Urology, 167, 65-70. https://doi.org/10.1016/S0022-5347(05)65384-0
|
[5]
|
Lebacle, C., Pooli, A., Bessede, T., et al. (2019) Epidemiol-ogy, Biology and Treatment Of Sarcomatoid RCC: Current State of the Art. World Journal of Urology, 37, 115-123. https://doi.org/10.1007/s00345-018-2355-y
|
[6]
|
Schieda, N., Thornhill, R.E., Al-Subhi, M., et al. (2015) Diagno-sis of Sarcomatoid Renal Cell Carcinoma with CT: Evaluation by Qualitative Imaging Features and Texture Analysis. AJR American Journal of Roentgenology, 204, 1013-1023. https://doi.org/10.2214/AJR.14.13279
|
[7]
|
Takeuchi, M., Kawai, T., Suzuki, T., et al. (2015) MRI for Differentiation of Renal Cell Carcinoma with Sarcomatoid Component from Other Renal Tumor Types. Abdominal Imaging, 40, 112-119.
https://doi.org/10.1007/s00261-014-0185-y
|
[8]
|
Rosenkrantz, A.B., Chandarana, H. and Melamed, J. (2011) MRI Findings of Sarcomatoid Renal Cell Carcinoma in Nine Cases. Clinical Imaging, 35, 459-464. https://doi.org/10.1016/j.clinimag.2010.11.002
|
[9]
|
Gao, J., Xu, Q., Fu, Y., et al. (2021) Comprehensive Evalua-tion of 68Ga-PSMA-11 PET/CT Parameters for Discriminating Pathological Characteristics in Primary Clear-Cell Renal Cell Carcinoma. European Journal of Nuclear Medicine and Molecular Imaging, 48, 561-569. https://doi.org/10.1007/s00259-020-04916-6
|
[10]
|
de Peralta-Venturina, M., Moch, H., Amin, M., et al. (2001) Sarcomatoid Differentiation in Renal Cell Carcinoma: A Study of 101 Cases. The American Journal of Surgical Pathol-ogy, 25, 275-284.
https://doi.org/10.1097/00000478-200103000-00001
|
[11]
|
Cheville, J.C., Lohse, C.M., Zincke, H., et al. (2004) Sarcomatoid Renal Cell Carcinoma: An Examination of Underlying Histologic Subtype and an Analysis of Associations with Patient Outcome. The American Journal of Surgical Pathology, 28, 435-441. https://doi.org/10.1097/00000478-200404000-00002
|
[12]
|
Kuroda, N., Tamura, M., Hamaguchi, N., et al. (2011) Acquired Cystic Disease-Associated Renal Cell Carcinoma with Sarcomatoid Change and Rhabdoid Features. Annals of Diagnostic Pathology, 15, 462-466.
https://doi.org/10.1016/j.anndiagpath.2010.07.008
|
[13]
|
Tong, G.-X., Yu, W.M., Beaubier, N.T., et al. (2009) Ex-pression of PAX8 in Normal and Neoplastic Renal Tissues: An Immunohistochemical Study. Modern Pathology, 22, 1218-1227. https://doi.org/10.1038/modpathol.2009.88
|
[14]
|
Ozcan, A., de la Roza, G., Ro, J.Y., Shen, S.S. and Truong, L.D. (2012) PAX2 and PAX8 Expression in Primary and Metastatic Renal Tumors: A Comprehensive Com-parison. Archives of Pathology & Laboratory Medicine, 136, 1541-1551.
https://doi.org/10.5858/arpa.2012-0072-OA
|
[15]
|
Tickoo, S.K., Alden, D., Olgac, S., et al. (2007) Immunohisto-chemical Expression of Hypoxia Inducible Factor-1α and Its Downstream Molecules in Sarcomatoid Renal Cell Carci-noma. The Journal of Urology, 177, 1258-1263.
https://doi.org/10.1016/j.juro.2006.11.100
|
[16]
|
Alevizakos, M., Gaitanidis, A., Nasioudis, D., Msaouel, P. and Appleman, L.J. (2019) Sarcomatoid Renal Cell Carcinoma: Population-Based Study of 879 Patients. Clinical Genitouri-nary Cancer, 17, e447-e453.
https://doi.org/10.1016/j.clgc.2019.01.005
|
[17]
|
Merrill, M.M., Wood, C.G, Tannir, N.M., et al. (2015) Clinically Nonmetastatic Renal Cell Carcinoma with Sarcomatoid Dedifferentiation: Natural History and Outcomes after Surgical Resection with Curative Intent. Urologic Oncology: Seminars and Original Investigations, 33, 166.e21-166.e29. https://doi.org/10.1016/j.urolonc.2014.11.021
|
[18]
|
Kutikov, A., Uzzo, R.G., Caraway, A., et al. (2010) Use of Systemic Therapy and factors Affecting Survival for Patients Undergoing Cytoreductive Nephrectomy. BJU Internation-al, 106, 218-223.
https://doi.org/10.1111/j.1464-410X.2009.09079.x
|
[19]
|
Abel, E.J., Carrasco, A., Culp, S.H., et al. (2012) Limita-tions of Preoperative Biopsy in Patients with Metastatic Renal Cell Carcinoma: Comparison to Surgical Pathology in 405 Cases. BJU International, 110, 1742-1746.
https://doi.org/10.1111/j.1464-410X.2012.11124.x
|
[20]
|
Keskin, S.K., Msaouel, P., Hess, K.R., et al. (2017) Out-comes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies: Comparison between the Cytokine and Targeted Therapy Eras. The Journal of Urology, 198, 530-537. https://doi.org/10.1016/j.juro.2017.04.067
|
[21]
|
Shuch, B., Said, J., La Rochelle, J.C., et al. (2009) Cytoreductive Nephrectomy for Kidney Cancer with Sarcomatoid Histology—Is up-Front Resection Indicated and, If Not, Is It Avoida-ble? The Journal of Urology, 182, 2164-2171.
https://doi.org/10.1016/j.juro.2009.07.049
|
[22]
|
Siva, S., Kothari, G., Muacevic, A., et al. (2017) Radiotherapy for Renal Cell Carcinoma: Renaissance of an Overlooked Approach. Nature Reviews Urology, 14, 549-563. https://doi.org/10.1038/nrurol.2017.87
|
[23]
|
Kunene, V., Miscoria, M., Pirrie, S., et al. (2014) Sarcomatoid Renal Cell Carcinoma: Clinical Outcome and Survival after Treatment with Sunitinib. Clinical Genitourinary Cancer, 12, 251-255. https://doi.org/10.1016/j.clgc.2013.12.001
|
[24]
|
Joseph, R.W., Millis, S.Z., Carballido, E.M., et al. (2015) PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation. Cancer Immunology Research, 3, 1303-1307.
https://doi.org/10.1158/2326-6066.CIR-15-0150
|
[25]
|
El Mouallem, N., Smith, S.C. and Paul, A.K. (2018) Com-plete Response of a Patient with Metastatic Sarcomatoid Renal Cell Carcinoma to a Programmed Death-1 Checkpoint In-hibitor. Journal of Oncology Practice, 14, 511-513.
https://doi.org/10.1200/JOP.18.00213
|
[26]
|
Gupta, S., Cheville, J.C., Jungbluth, A.A., et al. (2019) JAK2/PD-L1/PD-L2 (9p24.1) Amplifications in Renal Cell Carcinomas with Sarcomatoid Transformation: Implications for Clinical Management. Modern Pathology, 32, 1344-1358.
https://doi.org/10.1038/s41379-019-0269-x
|